Treatment of steroid-resistant nephrotic syndrome in children: new guidelines from KDIGO

Kidney Disease: Improving Global Outcomes (KDIGO) recently published the clinical practice guideline on glomerulonephritis (GN) to assist the practitioner caring for patients with GN. Chapter 4 of the guideline focuses on managing children aged 1–18 years with steroid-resistant nephrotic syndrome (S...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric nephrology (Berlin, West) West), 2013-03, Vol.28 (3), p.409-414
Main Authors: Lombel, Rebecca M., Hodson, Elisabeth M., Gipson, Debbie S.
Format: Article
Language:English
Subjects:
Adolescent
Adrenal Cortex Hormones - therapeutic use
Biopsy
Care and treatment
Child
Child, Preschool
Children
Clinical medicine
Clinical practice guidelines
Clinical trials
Complications and side effects
Consensus
Educational Review
Evaluation
Evidence-Based Medicine - standards
Health aspects
Hospitals
Humans
Immunosuppressive Agents - therapeutic use
Infant
Kidney diseases
Medical prognosis
Medicine
Medicine & Public Health
Mutation
Nephrology
Nephrology - standards
Nephrotic syndrome
Nephrotic Syndrome - congenital
Nephrotic Syndrome - diagnosis
Nephrotic Syndrome - drug therapy
Observational studies
Pediatrics
Proteins
Remission (Medicine)
Remission Induction
Steroids
Treatment Outcome
Urology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Kidney Disease: Improving Global Outcomes (KDIGO) recently published the clinical practice guideline on glomerulonephritis (GN) to assist the practitioner caring for patients with GN. Chapter 4 of the guideline focuses on managing children aged 1–18 years with steroid-resistant nephrotic syndrome (SRNS), defined by an inability to achieve complete remission with corticosteroid therapy. Guideline development followed a thorough evidence review, and management recommendations and suggestions were based on the best available evidence. Limitations of the evidence, including the paucity of large-scale randomized controlled trials, are discussed. This article provides both the guideline recommendations and a brief review of relevant treatment trials related to each recommendation. This précis serves as a summary of the complete guidelines recently published.
ISSN:0931-041X
1432-198X
DOI:10.1007/s00467-012-2304-8